Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Clinical trial NCT02184572 · COMPLETED

Trial details

NCT number: NCT02184572
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Measles; Mumps; Rubella Measles-Mumps-Rubella Vaccine

Start date: 2014-08-25
Primary completion: 2015-08-14
Enrollment: 1742

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.